NEFL and myeloid sarcoma: As noted in MS, in presymptomatic AD subjects, serum NfL peaked at the time of symptoms appearance, suggesting an acceleration in neuronal loss at the border zone between presymptomatic and symptomatic stages (Preische et al., 2019).